HIV DNA vaccine topical - Genetic Immunity

Drug Profile

HIV DNA vaccine topical - Genetic Immunity

Alternative Names: DermaVir Patch; LC002; Therapeutic DNA dendritic cell vaccine for HIV infections - Genetic Immunity

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genetic Immunity LLC
  • Developer Genetic Immunity; Karolinska Institute; National Institute of Allergy and Infectious Diseases; Virostatics
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-1-infections in Hungary (Topical, Patch)
  • 24 Jul 2015 DermaVir® is still in active development for HIV-1 infections in Germany, Italy, Sweden, USA and Hungary
  • 18 May 2012 Genetic Immunity plans a phase II trial for Hepatitis C and HIV-1 co-infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top